EATG » Hepatitis

Hepatitis

Phase 2b study of JNJ-4178 in chronic HCV initiated

NEW HAVEN, Conn., Nov. 30, 2016 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the start of patient dosing in a global Phase 2b open-label OMEGA-1 study of JNJ-4178, a 3DAA combination…

Hepatitis C virus infection is rising among gay and bisexual men in San Diego

The prevalence of hepatitis C virus (HCV) infection among HIV-positive men who have sex with men in San Diego has increased over the past 15 years, especially among men who…

Hepatitis C sheds enough in the rectum to transmit through anal sex

Researchers have come up with the first direct evidence that enough hepatitis C virus (HCV) sheds into the rectums of HIV-positive men who have sex with men (MSM) to transmit…

Mylan signs sub-license agreement with the Medicines Patent Pool for hepatitis C treatment

Mylan signs sub-license agreement with the Medicines Patent Pool to increase access to hepatitis C treatment in developing countries HERTFORDSHIRE, England and BENGALURU, India, Nov. 28, 2016 -- Mylan N.V.…

Non-adherence most important risk factor for sofosbuvir/ledipasvir failure

Research carried out by Mount Sinai Medical Center, New York, found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni). The main reasons cited…

Portal hypertension less likely to fall after HCV treatment when liver stiffness is severe

Curing hepatitis C infection moderately reduces portal hypertension, but has less impact in people with more severe liver stiffness due to fibrosis, Spanish researchers reported at the 2016 AASLD Liver…

ECDC review: Hepatitis B and C prevalence in the EU/EEA

A new ECDC review estimates the prevalence of both hepatitis B and C infection at around 1 percent respectively in the countries of the European Union and European Economic Area.…

Hep C treatment prognosis continues to amaze

Rapid advances in the treatment of hepatitis C have clinicians seeing outcomes they never thought possible, and experts are optimistic that more complex and challenging patients will respond to therapy. However,…

Nucleic acid polymers reduce HBsAg levels and improve control of hepatitis B virus

The nucleic acid polymers REP 2139 and REP 2165 led to hepatitis B surface antigen (HBsAg) reduction or clearance when combined with tenofovir and pegylated interferon, according to early results…

Sofosbuvir/ledipasvir effective for HIV/HCV coinfected people in real-world cohorts

The sofosbuvir/ledipasvir (Harvoni) coformulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people coinfected with hepatitis C, according to a pooled analysis presented at the 2016 AASLD Liver…